Skip to main content

Will Biotech ETFs Benefit from Biogen’s New Alzheimer’s Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen’s Alzheimer’s disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to help the mental deterioration seen in people living with Alzheimer’s. The drug is also the first...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.